Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials

INTRODUCTION: The long-acting muscarinic antagonist tiotropium bromide is approved in many countries as maintenance therapy for chronic obstructive pulmonary disease (COPD). Tiotropium is available as a dry-powder formulation delivered via HandiHaler(®) (18 μg once daily) and is now also approved as...

Descripción completa

Detalles Bibliográficos
Autores principales: Calverley, Peter M. A., Könen-Bergmann, Michael, Richard, Frank, Bell, Susan, Hohlfeld, Jens M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882367/
https://www.ncbi.nlm.nih.gov/pubmed/27084728
http://dx.doi.org/10.1007/s12325-016-0322-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882367/
https://www.ncbi.nlm.nih.gov/pubmed/27084728
http://dx.doi.org/10.1007/s12325-016-0322-9

Ejemplares similares